The tweet was deleted by the author.
But we saved everything 🙂.
UroGen Pharma said Chairman Arie Belldegrun, MD, will participate in a Fireside Chat on Thursday, July 23, from 12:00-12:30 PM ET in Boston, MA.
He will join the session titled 'Innovation, Investment, and the Future of Kidney Cancer Research' at #KCRS26. More information is available through the company's provided links.
View post on X Loading...
URGN is currently trading at $42.13, well above the MA-20 ($38.54), MA-50 ($33.19), and MA-200 ($24.25), which shows strong bullish momentum across short-, medium-, and long-term trends. The Ichimoku Kijun on D1 sits at $36.70, categorizing it as immediate support; near-term support is found at MA-20 ($38.54) and key support at MA-50 ($33.19), with near-term resistance at $43.93 (52-week high, slightly above the price) and key resistance at $46.45 if upside extends.
Momentum indicators are firmly bullish on D1, with MACD and ADX signaling persistent upward strength. RSI is elevated at 69.79, approaching overbought territory, while CCI is overbought at 145.41 and Stoch RSI signals an oversold reading—indicating divergence among oscillators. BBP points to buyer dominance, reinforcing bullish intraday sentiment, and the Awesome Oscillator supports the prevailing trend. URGN has risen $1.90 (4.92%) over the past week from a prev_week_close of $40.23, and is now middle in the weekly price range. Weekly volatility stands at 11.22%. Price action reflects consolidation after recent gains, with momentum and oscillators showing mixed short-term signals.
Looking ahead, the projected range for the coming week is $40.00 to $46.00, keeping current price within 5–10% of both ends for realism, and anchored between the $15.86 yearly low and the $43.93 high. The probability of further upside is very high (more than 80%) given unanimous "Buy" signals from RSI, ADX, MACD, and MA-50 on W1, making downside much less likely. The baseline scenario is consolidation within $40.00–$46.00. A bullish breakout above resistance could test new yearly highs if buying pressure persists. Conversely, a bearish scenario would emerge only if price closes below the $38.54–$36.70 support cluster, which remains unlikely given current momentum.
Earlier, analysts noted that UroGen Pharma demonstrated continued bullish momentum, supported by strong technical signals despite emerging resistance. In this context, investors should monitor for any shifts away from consolidation, as a decisive move could establish the next trend direction.